Core Viewpoint - The company, Innovent Biologics (09969.HK), announced that it will release its Q3 2025 financial report on November 14, 2025, and will hold a performance briefing to discuss the results and address investor concerns [1] Group 1 - The company plans to hold a performance briefing on November 14, 2025, from 11:00 AM to 12:00 PM [1] - The briefing aims to provide investors with a comprehensive understanding of the company's Q3 2025 operational results and financial status [1] - The event will facilitate communication regarding issues of interest to investors [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 InnoCare Pharma Limited 諾誠健華醫藥有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：9969） 诺诚健华医药有限公司 海外監管公告 本公告乃諾誠健華醫藥有限公司（「本公司」）根據香港聯合交易所有限公司證 券上市規則第13.10B條作出。 茲載列本公司於上海證券交易所網站刊登之《關於召開2025年第三季度業績說 明會的公告》。 承董事會命 諾誠健華醫藥有限公司 主席兼執行董事 崔霽松博士 香港，二零二五年十一月五日 於本公告日期，董事會包括主席兼執行董事崔霽松博士；執行董事趙仁濱博士；非執行董事 施一公博士及謝榕剛先生；以及獨立非執行董事胡蘭女士、董丹丹博士及管坤良教授。 | A | 股代码：688428 | 股简称：诺诚健华 A | 公告编号：2025-037 | | --- | --- | --- | --- | | 港股代码：09969 ...

致：香港交易及結算所有限公司 公司名稱: 諾誠健華醫藥有限公司（於開曼群島註冊成立的有限公司） 呈交日期: 2025年11月5日 FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09969 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 25,000,000,000 | USD | | 0.000002 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 25,000,000,000 | USD | | 0.000002 | U ...

Core Insights - The Science and Technology Innovation Board (STAR Market) has successfully gathered 592 listed companies by October 2025, with a cumulative IPO fundraising scale of 934.6 billion yuan and total financing exceeding 1.1 trillion yuan, becoming a key force in nurturing new productive forces and upgrading the modern industrial system [1][2] - Over the past five years, STAR Market companies have shown strong growth, with a compound annual growth rate of 18% in operating income and 9% in net profit attributable to shareholders, indicating robust growth potential [2][3] - The STAR Market has established a virtuous cycle ecosystem of "technology - industry - capital," effectively promoting the efficient allocation of innovative resources and attracting talent and investment [6][8] Group 1: Financial Performance - By October 2025, the STAR Market has raised a total of 934.6 billion yuan through IPOs, with total financing surpassing 1.1 trillion yuan [1] - The compound annual growth rates for operating income and net profit attributable to shareholders for STAR Market companies are 18% and 9%, respectively, since 2019 [2] - In the integrated circuit sector, 119 disclosed companies reported a revenue growth of 27% and a net profit growth of 83% year-on-year for the first three quarters of 2025 [3] Group 2: Industry Focus and Innovation - The STAR Market has maintained a focus on "hard technology," with over 80% of listed companies in emerging industries such as new-generation information technology, biomedicine, and high-end equipment manufacturing [3] - The STAR Market has seen significant advancements in key technologies, with companies like He Yuan Bio and Guo Dun Quantum achieving breakthroughs in innovative drugs and semiconductor technologies [4] - As of 2025, STAR Market companies have formed over 130,000 invention patents, with an average of 230 patents per company, showcasing a strong emphasis on innovation [4][5] Group 3: Ecosystem and Market Dynamics - The STAR Market has successfully attracted over 60% of its founding teams from scientific and engineering backgrounds, fostering a culture of innovation [6] - Approximately 90% of STAR Market companies received venture capital investment before going public, indicating strong investor confidence [6] - The STAR Market has developed a comprehensive index system with 33 indices, and the total scale of STAR Market-related index tracking products exceeds 330 billion yuan [6][7] Group 4: Regulatory and Institutional Innovations - The STAR Market has pioneered various institutional innovations, including multi-dimensional listing standards and a small-scale rapid financing mechanism, providing valuable lessons for other market segments [8] - Recent reforms, such as the "1+6" initiative, have further enhanced the inclusivity of the STAR Market, allowing for the expansion of standards to cover cutting-edge fields like artificial intelligence [8] - The Shanghai Stock Exchange aims to leverage the STAR Market's role as a "testing ground" to better identify high-quality technology enterprises and support their listing [9]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 呈交日期: 2025年11月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09969 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 25,000,000,000 | USD | | 0.000002 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 25,000,000,000 | USD | | 0.000002 | USD | | 50,000 | 本月底法定/註冊股本總額： USD ...

Core Insights - A total of 77 stocks in the Shanghai and Shenzhen markets have experienced net inflows of main funds for five consecutive days or more as of November 5, with Cambricon Technologies (寒武纪-U) leading with 50 days of continuous inflow [1] - The total net inflow of main funds for Cambricon Technologies reached 6.325 billion yuan, followed by Shanghai Pudong Development Bank with a net inflow of 777 million yuan over five days [1] - In terms of the proportion of net inflow to trading volume, *ST Baoying ranks first, with a 47.72% increase over the past eight days [1] Summary by Category Stocks with Continuous Net Inflows - Cambricon Technologies (688256) has seen net inflows for 50 days totaling 6.325 billion yuan, with a price increase of 44.33% [1] - Shanghai Pudong Development Bank (600000) recorded net inflows of 777 million yuan over five days, with a price increase of 0.42% [1] - CITIC Bank (601998) had net inflows of 439 million yuan over six days, with a price increase of 3.85% [1] Notable Performers - *ST Baoying had the highest net inflow ratio, with a significant price increase of 47.72% over the last eight days [1] - Other notable stocks include Jiangsu Bank (600919) with a net inflow of 342 million yuan and a price increase of 5.70%, and Yaxing Anchor Chain (601890) with a net inflow of 331 million yuan and a price increase of 10.16% [1] Additional Stocks with Inflows - Other stocks with notable net inflows include: - China Shenhua (601088) with 314 million yuan and a 3.42% increase [1] - Haotian Co., Ltd. (603759) with 166 million yuan and a 64.35% increase over 11 days [1] - Microelectronic Physiology (688351) with 140 million yuan and a 12.94% increase [1]

| A | 股代码：688428 | 股简称：诺诚健华 A | 公告编号：2025-037 | | --- | --- | --- | --- | | 港股代码：09969 | | 港股简称：诺诚健华 | | 诺诚健华医药有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2025 年 11 月 14 日(星期五)上午 11:00-12:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 11 月 7 日(星期五)至 11 月 13 日(星期四)16:00 前登 录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 IR@innocarepharma.com 进行提问。公司将在说明会上对投资者普遍关注的问题 进 ...

Core Insights - The "2025 China Biotechnology Innovation Conference" highlighted the competitive evaluation of China's biopharmaceutical industry parks, with Zhongguancun Demonstration Zone ranking first in overall competitiveness [1] - The report assessed 208 parks based on five primary indicators: environmental competitiveness, industrial competitiveness, technological competitiveness, talent competitiveness, and collaborative competitiveness [1] - Zhongguancun demonstrated top rankings in three of the five primary indicators, showcasing its strong position in the biopharmaceutical sector [1] Group 1 - Zhongguancun's comprehensive competitiveness is illustrated through various innovative success stories, such as the establishment of Innovent Biologics, which focuses on unmet clinical needs in hematology and autoimmune diseases [2] - The company has developed the cancer drug Orelabrutinib, which is expanding its commercial reach globally while benefiting domestic patients [2] - Other notable advancements include the AI-enabled drug MTS-004 completing phase III clinical trials and the GA001 injection receiving FDA fast track designation [2] Group 2 - Beijing aims to leverage its status as an international science and technology innovation center to build a modern biopharmaceutical industry cluster [2] - The city plans to enhance collaboration among universities, research institutes, hospitals, and innovative enterprises to improve drug research and development efficiency [2] - Initiatives include the establishment of shared scientific facilities, pilot platforms, and clinical trial collaborations, as well as the optimization of the industrial supply chain [2]

Core Insights - The article highlights the resurgence of US dollar funds in the Chinese innovative drug market, with significant investments and licensing deals indicating a renewed interest in this sector [1][4][5]. Group 1: Investment Trends - In 2025, Heng Rui Medicine completed a licensing agreement with Braveheart Bio for the HRS-1893 project, with an upfront payment of $65 million and a total deal value of up to $1.013 billion, marking the fourth business development (BD) deal for Heng Rui this year, totaling over $15 billion [1]. - In the first half of 2025, the total value of outbound licensing deals for Chinese innovative drugs reached $48.448 billion, nearing the total for the entire year of 2024, with over 80% of these deals involving US dollar funds [4]. - The return of US dollar funds to the Chinese innovative drug market is characterized by a shift from direct investments to more strategic BD transactions, focusing on specific drug pipelines and products rather than entire companies [13][14]. Group 2: Market Dynamics - The article notes that from 2024 to 2030, major pharmaceutical companies in the US and Europe will face a revenue gap of approximately $360 billion due to patent expirations, prompting them to seek acquisitions in the Chinese innovative drug sector to fill this void [9]. - The quality of Chinese innovative drugs has significantly improved, with over 1,250 new drugs entering the research phase in 2024, closely approaching the number in the US [11]. - The competitive landscape has intensified, with not only US dollar funds but also European, Middle Eastern, and East Asian capital increasingly targeting Chinese innovative drug assets, leading to heightened competition for quality investments [12]. Group 3: Strategic Shifts - US dollar funds are transitioning from a broad investment strategy to a more focused approach, emphasizing "certainty first" in their investment decisions, which includes a preference for assets with clear international market potential [13][14]. - The NewCo model is gaining traction, allowing for deeper collaboration between US dollar funds and Chinese innovative drug companies, sharing risks and benefits more equitably [15][16]. - The article suggests that the current environment presents a strategic opportunity for Chinese innovative drug companies to leverage US dollar fund investments while maintaining a focus on original innovation and enhancing the value of their drug pipelines [23][24].

Core Insights - The establishment of the Overseas Returnee Town in Guangzhou's Huangpu District has attracted around 30 well-known innovative enterprises and projects, creating a vibrant entrepreneurial ecosystem for returnees [3][5][11] - The region has developed a complete biopharmaceutical industry chain, facilitating research, transformation, and production, which supports companies at various stages of development [3][5][11] - The "1+N" multi-core model of the town promotes regional collaboration and has become a hub for returnee talent to start their businesses [4][5] Industry Development - The core area of the Overseas Returnee Town spans 3.8 square kilometers, with an additional 4.2 square kilometers for future expansion, forming a comprehensive biopharmaceutical innovation ecosystem [5] - Leading companies such as BeiGene, CanSino Biologics, and Innovent Biologics have established a presence in the town, contributing cutting-edge ideas and technologies while attracting more overseas talent [5][6] - The dual-center support system, including the Phoenix Valley Returnee Center and the International Biopharmaceutical Innovation Center, provides comprehensive services for the ecosystem [5][6] Talent and Investment - The returnee town is strategically aligned with the industrial upgrade of Guangzhou, which has recognized the potential of the biopharmaceutical sector since the late 1990s [7][8] - The government has implemented innovative models combining physical space provision, talent attraction, and market-oriented management, with a guiding fund of 2 billion yuan aimed at attracting social capital [8] - Approximately 76.11 billion yuan has been invested in 274 enterprises, with 18.54 billion yuan specifically directed towards returnee startups [11] Innovation and Collaboration - The Guangzhou National Laboratory on the Biopharmaceutical Island has successfully attracted high-level researchers from abroad, facilitating the transformation of research outcomes into industry applications [9] - The region is focusing on international collaborations, leveraging its advantages in scientific research to establish a leading position in biopharmaceutical innovation [8][9] - The integration of various resources has created a robust innovation network, with around 4,800 biopharmaceutical companies thriving in the area [11]